`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF DELAWARE
`
`) )
`
`) Civil Action No.
`
`) )
`
`BAYER HEALTHCARE LLC, et al.
`
`v.
`TEVA PHARMACEUTICALS USA, INC., et
`al.
`
`SUPPLEMENTAL INFORMATION FOR PATENT CASES
`INVOLVING AN ABBREVIATED NEW DRUG APPLICATION (ANDA)
`
`Plaintiff(s) hereby provide(s) the information below with respect to the deadlines set
`forth in 21 U.S.C. 355(j):
`
`On or about 11/23/2016
`Date Patentee(s) Received Notice: ______________________
`
`See Below*
`Date of Expiration of Patent: ________________________
`
`*
`
`3/27/2020**
`Thirty Month Stay Deadline: ________________________
`7,351,834 - January 12, 2020+
`8,680,124 - June 2, 2030
`8,637,553 - February 16, 2031
`9,458,107 - April 8, 2031
`+ This expiration date is expected to be extended to June 28, 2022 as a result of a patent term extension pursuant
`to 35 U.S.C. § 156.
`
`This deadline is calculated pursuant to New Chemical Entity status, which applies in this case.
`**
`/s/ Jack B. Blumenfeld
`12/16/2016
`_________________________________
`_________________
` Attorney(s) for Plaintiff
`Date
`
`